中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2010年
7期
475-477
,共3页
董恂玮%张立鹏%赵玉平%郑以州%张凤奎%杨仁池
董恂瑋%張立鵬%趙玉平%鄭以州%張鳳奎%楊仁池
동순위%장립붕%조옥평%정이주%장봉규%양인지
Evans综合征%贫血,溶血性,自身免疫性%紫癜,血小板减少性,特发性
Evans綜閤徵%貧血,溶血性,自身免疫性%紫癜,血小闆減少性,特髮性
Evans종합정%빈혈,용혈성,자신면역성%자전,혈소판감소성,특발성
Evans syndrome%Anaemia,haemolytic,autoimmune%Purpura,thrombocytopenic,idiopathic
目的 探讨成人Evans综合征的初始临床特征,各种治疗方法 的疗效及病程.方法 对84例成人Evans综合征患者(男20例,女64例)应用激素、丙种免疫球蛋白、免疫抑制剂多药联合治疗,中位随访17.5(0.03~140)个月,观察患者起病特征及临床疗效.结果 所有患者均接受激素加或不加静脉丙种免疫球蛋白初始治疗.47例患者单用激素治疗,其中38例达完全缓解(CR)和部分缓解(PR).中位随访12个月,92.1%的患者复发.28例对激素耐药或出现严重出血的患者随后给予免疫抑制剂治疗,89.3%的患者获得CR或PR.中位随访8个月,84%患者复发.结论 Evans 综合征难治且易复发,联合治疗可能是治疗Evans综合征的有效手段.
目的 探討成人Evans綜閤徵的初始臨床特徵,各種治療方法 的療效及病程.方法 對84例成人Evans綜閤徵患者(男20例,女64例)應用激素、丙種免疫毬蛋白、免疫抑製劑多藥聯閤治療,中位隨訪17.5(0.03~140)箇月,觀察患者起病特徵及臨床療效.結果 所有患者均接受激素加或不加靜脈丙種免疫毬蛋白初始治療.47例患者單用激素治療,其中38例達完全緩解(CR)和部分緩解(PR).中位隨訪12箇月,92.1%的患者複髮.28例對激素耐藥或齣現嚴重齣血的患者隨後給予免疫抑製劑治療,89.3%的患者穫得CR或PR.中位隨訪8箇月,84%患者複髮.結論 Evans 綜閤徵難治且易複髮,聯閤治療可能是治療Evans綜閤徵的有效手段.
목적 탐토성인Evans종합정적초시림상특정,각충치료방법 적료효급병정.방법 대84례성인Evans종합정환자(남20례,녀64례)응용격소、병충면역구단백、면역억제제다약연합치료,중위수방17.5(0.03~140)개월,관찰환자기병특정급림상료효.결과 소유환자균접수격소가혹불가정맥병충면역구단백초시치료.47례환자단용격소치료,기중38례체완전완해(CR)화부분완해(PR).중위수방12개월,92.1%적환자복발.28례대격소내약혹출현엄중출혈적환자수후급여면역억제제치료,89.3%적환자획득CR혹PR.중위수방8개월,84%환자복발.결론 Evans 종합정난치차역복발,연합치료가능시치료Evans종합정적유효수단.
Objective To evaluate the initial clinical characteristics, the response to treatment, and the outcome in adult patients with Evans syndrome. Methods The clinical data of 84 adult patients (20 males, 64 females) with Evans syndrome diagnosed at our center between 1984 and 2007 were retrospectively analyzed. Results The patients were followed up for a median duration of 17.5 (0.03-140) months. All the patients initially received intravenous steroids with or without intravenous immunoglobulin (IVIG). Forty-seven patients were treated with corticosteroids alone initially. Complete remission (CR) and partial remission (PR) were achieved in 38 of the patients, but 92. 1% of them relapsed during a median follow-up of 12 months. Twenty-eight patients who were resistant to corticosteroids therapy or with severe bleeding were subsequently administered immunosupressive agents. CR and PR were obtained in 89.3% of them. Within a median follow-up of 8 months, 84% of these patients relapsed. Conclusions Evans syndrome is a chronic and easy to recurrent disease, which is often refractory to conventional therapy. Treatment with combination agents might be a useful therapeutic approach to the patients.